Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits

Brain Research

Volumn 821, Issue 2, 1999, Pages 433-442

  Oh, Justin D ^a   Vaughan, Christina L ^a   Chase, Thomas N ^a  

^a Sect Clin and Exp Neuropsychol   (United States)

Author keywords

6 Hydroxydopamine lesion; Basal ganglia; KN93; Motor response alterations; NMDA antagonist; Parkinson's disease

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; PROTEIN KINASE (CALCIUM,CALMODULIN) II; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DENERVATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MALE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR SENSITIVITY; SENSITIZATION; WESTERN BLOTTING;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTIBODIES; ANTIPARKINSON AGENTS; BENZYLAMINES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; ENZYME INHIBITORS; LEVODOPA; MALE; MOTOR NEURONS; NERVE DEGENERATION; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PHOSPHORYLATION; PHOSPHOSERINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; SULFONAMIDES; SYMPATHOLYTICS;

EID: 0033550940     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01121-X     Document Type: Article

References (73)

1. P.J. Blanchet, S. Konitsiotis, E.R. Whittemore, Z.L. Zhou, R.M. Woodward, T.N. Chase, Differing effects of NMDA receptor antagonists on dyskinesia in levodopa-primed MPTP monkeys, 1998, submitted.
2. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997;447-453.
3. Blanchet P.J., Verhagen M.L., Mouradian M.M., Chase T.N. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov. Disord. 11:1996;580-581.
4. Blandini F., Greenamyre J.T. Prospects of glutamate antagonists in the therapy of Parkinson's disease. Fundam. Clin. Pharmacol. 12:1998;4-12.
5. Bortolotto Z.A., Collingridge G.L. Involvement of calcium/calmodulin-dependent protein kinases in the setting of a molecular switch involved in hippocampal LTP. Neuropharmacology. 37:1998;535-544.
6. Bravi D., Mouradian M.M., Roberts J.W., Davis T.L., Shon Y.H., Chase T.N. Wearing-off fluctuations in parkinson's disease: contribution of postsynaptic mechanisms. Ann. Neurol. 36:1994;27-31.
7. 2+ in striatal LTD and LTP. Semin. Neurosci. 8:1996;321-328.
8. Cervo L., Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res. 731:1996;31-38.
9. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 55:1998;1-9.
10. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 51:1998;S30-S35.
11. Collingridge G.L., Bliss T.V.P. Memories of NMDA receptors and LTP. Trends Neurosci. 18:1995;54-56.
12. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
13. Engber T.M., Anderson J.J., Boldry R.C., Kuo S., Chase T.N. N-Methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D(1)-dopamine and D(2)-dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion. Neuroscience. 54:1993;1051-1061.
14. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588.
15. Fagnou D.D., Tuchek J.M. The biochemistry of learning and memory. Mol. Cell. Biochem. 149:1995;279-286.
16. Fukunaga K., Muller D., Miyamoto E. CaM kinase II in long-term potentiation. Neurochem. Int. 28:1996;343-358.
17. Gerfen C.R., Keefe K.A., Gauda E.B. D1 and D2 dopamine receptor function in the striatum: Coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J. Neurosci. 15:1995;8167-8176.
18. Giese K.P., Fedorov N.B., Filipkowski R.K., Silva A.J. Autophosphorylation at Thr(286) of the alpha calcium-calmodulin kinase II in LTP and learning. Science. 279:1998;870-873.
19. Gordon J.A., Cioffi D., Silva A.J., Stryker M.P. Deficient plasticity in the primary visual cortex of alpha-calcium/calmodulin-dependent protein kinase II mutant mice. Neuron. 17:1996;491-499.
20. Graybiel A.M., Aosaki T., Flaherty A.W., Kimura M. The basal ganglia and adaptive motor control. Science. 265:1994;1826-1831.
21. Greenamyre J.T., Eller R.V., Zhang Z.M., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of parkinsons-disease. Ann. Neurol. 35:1994;655-661.
22. Gurd J.W. Protein tyrosine phosphorylation: implications for synaptic function. Neurochem. Int. 31:1997;635-649.
23. Hall R.A., Solderling T.R. Differential surface expression and phosphorylation of the N-methyl-D-aspartate receptor subunits NR1 and NR2 in cultured hippocampal neurons. J. Biol. Chem. 272:1997;4135-4140.
24. Hayashi Y., Ishida A., Katagiri H., Mishina M., Fujisawa H., Manabe T., Takahashi T. Calcium- and calmodulin-dependent phosphorylation of AMPA type glutamate receptor subunits by endogenous protein kinases in the post-synaptic density. Mol. Brain Res. 46:1997;338-342.
25. Hemmings H.C. Jr., Nairin A.C., Mcguiness T.L., Huganir R.L., Greengard P. Role of protein phosphorylation in neuronal signal transduction. FASEB J. 3:1989;1583-1592.
26. Hisatsune C., Umemori H., Inoue T., Michikawa T., Kohda K., Mikoshiba K., Yamamoto T. Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin. J. Biol. Chem. 272:1997;20805-20810.
27. Hurtig H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp. Neurol. 144:1997;10-16.
28. Kennedy M.B. The postsynaptic density at glutamatergic synapses. Trends Neurosci. 20:1997;264-268.
29. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44:1994;163-196.
30. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate Interactions in Parkinson's Disease. Neurosci. Biobehav. Rev. 21:1997;393-400.
31. Lau I.F., Huganir R.L. Differential tyrosine phosphorylation of N-methyl-D-aspartate receptor subunits. J. Biol. Chem. 270:1995;20036-20041.
32. Le Moine C., Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355:1995;418-426.
33. Leonard A.S., Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J. Biol. Chem. 272:1997;12107-12115.
34. 2+-dependent phosphatase. Nature. 369:1994;235-239.
35. 2+/calmodulin-dependent protein kinase II inhibitor KN-93. Biophys. Res. Commun. 195:1993;608.
36. Marin C., Papa S.M., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
37. Mayford M., Bach M.E., Huang Y.Y., Hawkins R.D., Kandel E.R. Control of memory formation through regulated expression of a CaMKII transgene. Science. 274:1996;1678-1683.
38. Menegoz M., Lau L.F., Herve D., Huganir R.L., Girault J.A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effect of 6-OHDA dopamine lesions. NeuroReport. 7:1995;125-128.
39. Metman L.V., Blanchet P.J., Mouradian M.M., Chase T.N. Dextromethorphan and levodopa combination therapy in parkinson's patients with response fluctuations. Mov. Disord. 11:1996;184.
40. Metman L.V., Del Dotto P., Blanchet P.J., van den Munckhof P., Chase T.N. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14:1998;75-82.
41. Metman L.V., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
42. Metman L.V., Locatelli E.R., Bravi D., Mouradian M.M., Chase T.N. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 50:1998;574-574.
43. Mitchell I.J., Carroll C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci. Biobehav. Rev. 21:1997;469-475.
44. 2+ calmodulin-dependent protein-kinase-II. Molec. Cells. 5:1995;475-480.
45. Nestler E.J. Molecular neurobiology of drug-addiction. Neuropsychopharmacology. 11:1994;77-87.
46. Oh J.D., Del Dotto P., Chase T.N. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci. Lett. 228:1997;5-8.
47. J.D. Oh, D. Russell, C.L. Vaughan, T.N. Chase, Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and levodopa administration, Brain Res. (1998) in press.
48. Omkumar R.V., Kiely M.J., Rosenstein A.J., Min K.T., Kennedy M.B. Identification of a phosphorylation site for calcium/calmodulin-dependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 271:1996;31670-31678.
49. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18.
50. Papa S.M., Chase T.N. Levodopa-induced dyskinesia improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
51. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
52. Parent A., Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov. Disord. 13:1998;199-202.
53. Raymond L.A., Tingley W.G., Blackstone C.D., Roche K.W., Huganir R.L. Glutamate-receptor modulation by protein-phosphorylation. J. Physiol. (Paris). 88:1994;181-192.
54. Rodnight R., Wofchuuk S.T. Roles for protein phosphorylation in synaptic transmission. Essays Biochem. 27:1992;91-102.
55. Rostas J.A.P., Brent V.A., Voss K., Errington M.L., Bliss T.V.P., Gurd J.W. Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in long-term potentiation. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10452-10456.
56. Seasack S.R., Aoki C., Pickel V.M. Ultrastructural localization of D2-receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J. Neurosci. 14:1994;88-106.
57. Sigel E. Functional modulation of ligand-gated gaba(a) and NMDA receptor channels by phosphorylation. J. Recept. Signal Transduction Res. 15:1995;325-332.
58. Smith Y., Shink E., Sidibe M. Neuronal circuitry and synaptic connectivity of the basal ganglia. Neurosurg. Clin. N. Am. 9:1998;203.
59. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci. 13:1990;259-265.
60. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
61. Stefani A., Pisani A., Bernardi G., Bonci A., Mercuri N.B., Stratta F., Calabresi P. The modulation of dopamine receptors in rat striatum. J. Neural Transm. Suppl. 45:1995;61-66.
62. Tan S.E., Chen S.S. The activation of calcium/calmodulin-dependent protein-kinase II after glutamate or potassium stimulation in hippocampal slices. Brain Res. Bull. 43:1997;269-273.
63. Thiels E., Xie X.P., Yeckel M.F., Barrionuevo G., Berger T.W. NMDA receptor-dependent LTD in different subfields of hippocampus in vivo and in vitro. Hippocampus. 6:1996;43-51.
64. Tingley W.G., Ehler M.D., Kameyama K., Doherty C., Ptak J.B., Riley C.T., Huganir R.L. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272:1997;5157-5166.
65. Ulas J., Cotman C. Dopaminergic denervatiom of striatum results in elevated expression of NR2A subunit. NeuroReport. 7:1996;1789-1793.
66. 2+-sensitivity of cloned NMDA receptors. Neuropharmacology. 35:1996;29-36.
67. Wang Y.T., Salter M.W. Regulation of NMDA receptors by tyrosin kinases and phosphatases. Nature. 369:1994;233-235.
68. 2+/CAM induces synaptic potentiation requiring CaMKII and PKC activity. Neuron. 15:1995;443-452.
69. Wang L.Y., Orser B.A., Brautigan D.L., MacDonald J.F. Regulation of NMDA receptors in cultured hippocampal-neurons by protein phosphatase-1 and phosphatase-2A. Neuron. 16:1994;415-421.
70. Wickens J.R., Kotter R., Alexander M.E. Effects of local connectivity on striatal function - stimulation and analysis of a model. Synapse. 20:1995;281-298.
71. Wolfman C., Fin C., Dias M., Bianchin M., Da Silva R.C., Schmitz P.K., Medina J.H., Izquierdo I. Intrahippocampal or intra-amygdala infusion of KN62, a specific inhibitor of calcium/calmodulin dependent protein kinase II, causes retrograde amnesia in the rat. Behav. Neurol. Biol. 61:1994;203-205.
72. Wyneken U., Riquelme G., Villanueva S., Orrego F. Effect of glutamate receptor phosphorylation by endogenous protein kinases on electrical activity of isolated postsynaptic densities of rat cortex and hippocampus. Neurosci. Lett. 224:1997;131-135.
73. Yu X.M., Askalan R., Keil G.J., Salter M.W. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science. 275:1997;674-678.